Jump to content

Iratumumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 12:47, 11 August 2016 (Updating {{infobox_drug}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'Watchedfields') per Chem/infobox_drug validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Iratumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD30
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6358H9830N1682O1992S38
Molar mass170 kg/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.[1]

This drug was developed by Medarex, Inc.

References